ran has showcased three cutting-edge achievements in nuclear medicine as well as the launch of the national nuclear network. The unveiling ceremony took place at the Tehran International Exhibition Centre on the sidelines of the 26th International Exhibition of Research, Technology and Tech-Market. It was attended by Vice President Mohammad Reza Aref and Mohammad Eslami, head of the Atomic Energy Organisation of Iran (AEOI).

The products included: 68Ga-Alpha-MSH (Gallium-68 labelled Alpha-Melanocyte Stimulating Hormone), a radiotracer used for metastatic melanoma imaging with positron emission tomography (PET); 177Lu-Alpha-MSH (Lutetium-177 labelled Alpha-Melanocyte Stimulating Hormone), a promising targeted radiopharmaceutical for treating metastatic melanoma; and an automated system for producing radiopharmaceuticals to treat bone metastases.

In addition, the ceremony marked the operational launch of Iran’s National Nuclear Education Network, aimed at enhancing research capabilities and fostering collaboration across the country’s nuclear sector. Speaking at the ceremony, Eslami said AEOI has prioritised innovation and rapid transformation of ideas into products.

He noted that in 2023, during the same exhibition, Iran had reported the production of 50 radiopharmaceuticals with 20 more currently in the research phase. “Today, I would like to inform you that we have reached 70 radiopharmaceuticals,” he said.

In response to a question from reporters, he said that some 56 countries have been and continue express interest in Iranian medical equipment. “The demands and programmes we receive from applicants show that consumers are looking for them.”